Edition:
United States

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

163.33USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$163.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
269,751
52-wk High
$173.28
52-wk Low
$44.58

Latest Key Developments (Source: Significant Developments)

Sage Therapeutics Reports Positive Results From Phase 2 Placebo-Controlled Trial Of Sage-217 In Major Depressive Disorder
Thursday, 7 Dec 2017 06:00am EST 

Dec 7 (Reuters) - Sage Therapeutics Inc ::SAGE THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2 PLACEBO-CONTROLLED TRIAL OF SAGE-217 IN MAJOR DEPRESSIVE DISORDER.SAGE THERAPEUTICS - SAGE-217 MET PRIMARY ENDPOINT AND PROVIDED RAPID, DURABLE EFFECTS THROUGH 2-WEEK TREATMENT PERIOD AND ADDITIONAL 4-WEEK FOLLOW-UP.SAGE THERAPEUTICS - PHASE 2 TRIAL OF SAGE-217​ ‍WELL-TOLERATED.SAGE THERAPEUTICS INC - DATA FROM PHASE 2 STUDY SUPPORT FURTHER DEVELOPMENT OF SAGE-217 FOR MDD AND RELATED DISORDERS.SAGE THERAPEUTICS - SAGE-217 DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT MEAN REDUCTION IN HAM-D SCORE COMPARED TO PLACEBO AT 15 DAYS​.SAGE THERAPEUTICS INC - SAGE-217 HAD NO SERIOUS OR SEVERE ADVERSE EVENTS IN PHASE 2 STUDY.SAGE THERAPEUTICS - ALL SECONDARY ENDPOINTS WERE CONSISTENT WITH PRIMARY ENDPOINTS AT DAY 15 OF TRIAL OF SAGE-217.  Full Article

Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share
Tuesday, 14 Nov 2017 09:00pm EST 

Nov 14 (Reuters) - Sage Therapeutics Inc -:SAGE THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE.  Full Article

Sage Therapeutics announces proposed public offering of common stock
Monday, 13 Nov 2017 04:01pm EST 

Nov 13 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces proposed public offering of common stock.Sage Therapeutics Inc - ‍has commenced an underwritten public offering of $300.0 million of its common stock​.  Full Article

Sage Therapeutics announces Brexanolone achieves primary endpoints
Thursday, 9 Nov 2017 06:00am EST 

Nov 9 (Reuters) - Sage Therapeutics Inc ::Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression.Statistically significant mean reduction in HAM-D score compared to placebo at 60 hours demonstrated in both trials​.Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies​.Brexanolone achieved primary endpoint in both trials​.In each trial, 1 patient experienced serious adverse event; neither required hospitalization, 1 deemed not to be study-drug related​.Sage plans to file a New Drug Application (NDA) with U.S. Food and Drug Administration in 2018 for Brexanolone​.  Full Article

Sage Therapeutics announces qtrly loss per share $1.97‍​
Thursday, 2 Nov 2017 06:30am EDT 

Nov 2 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update.Qtrly loss per share $1.97‍​.  Full Article

Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone
Tuesday, 12 Sep 2017 06:00am EDT 

Sept 12 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone in super-refractory status epilepticus.Sage Therapeutics Inc - ‍study did not meet primary endpoint​.Sage Therapeutics Inc - ‍secondary endpoint results were consistent with primary endpoint in study​.Sage Therapeutics Inc - ‍rate of death was similar in brexanolone and placebo groups in study​.Sage Therapeutics Inc - ‍rate of adverse events leading to discontinuation of study drug was similar in brexanolone and placebo groups and was low overall​.Sage Therapeutics Inc - ‍serious adverse events were similar between two treatment groups in trial​.Sage Therapeutics - about 37 percent of patients treated with open-label brexanolone after end of double-blind period achieved treatment response​.  Full Article

Sage Therapeutics Q2 ‍net loss per $1.88​
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces second quarter 2017 financial results and provides pipeline update.Sage Therapeutics Inc - qtrly ‍net loss per share basic and diluted $1.88​.Q2 earnings per share view $-1.67 -- Thomson Reuters I/B/E/S.Sage Therapeutics Inc - ‍expects existing cash, cash equivalents, marketable securities will fund operating expenses, capex requirements, into Q2 of 2018​.  Full Article

Sage Therapeutics qtrly loss per share $1.52
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Sage Therapeutics Inc ::Sage therapeutics announces first quarter 2017 financial results and provides pipeline update.Qtrly loss per share $1.52.  Full Article

Sage Therapeutics posts Q4 loss per share of $1.50
Thursday, 23 Feb 2017 06:30am EST 

Sage Therapeutics Inc : Sage Therapeutics announces fourth quarter and full year 2016 financial results and provides corporate update . Expects existing cash, cash equivalents, to fund anticipated level of operations, based on its current operating plans, into Q2' 18 .Qtrly loss per share $1.50.  Full Article

Sage-547 granted prime designation by EMA for treatment of postpartum depression
Wednesday, 16 Nov 2016 09:40am EST 

Sage Therapeutics Inc : Sage-547 granted prime designation by EMA for the treatment of postpartum depression .Company now anticipates globalizing its PPD development program and establishing european clinical operations.  Full Article

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.